Kardigan Raises $254 Million Series B to Advance Personalized Cardiovascular Therapies
Kardigan, a biotechnology company developing personalized cardiovascular medicines, has announced the closing of a major US $254 million Series B funding round, marking one of the largest private financings in the heart-health sector this year. The company, which launched in early 2025, is focused on advancing a late-stage pipeline of targeted therapies designed to address some of the most pressing and underserved cardiovascular conditions.
The Series B round drew substantial interest from both new and returning institutional investors. New participants include Fidelity Management & Research Company and accounts advised by T. Rowe Price Investment Management, Inc.. They join returning backers ARCH Venture Partners and Sequoia Heritage, both of which also led Kardigan’s earlier financing. According to the company, the new capital will accelerate progress across its portfolio and support its aim of modernizing cardiovascular drug development.
This fundraising follows Kardigan’s emergence from stealth in January 2025, when it secured US $300 million in Series A financing. That round was led by ARCH Venture Partners and Sequoia Heritage, with participation from Perceptive Advisors. The company entered the market with an industry-leading capital base and a strategy centered on integrating data-driven insights with next-generation therapeutic design.
Kardigan plans to use the Series B funding to advance three lead clinical programs. The first targets certain genetic forms of dilated cardiomyopathy using a cardiac myosin activator designed to improve cardiac contractility. The second focuses on an investigational therapy for acute severe hypertension, a condition for which limited rapid-acting, targeted treatments currently exist. The third program involves the development of an oral therapy for calcific aortic valve stenosis, a progressive and potentially fatal condition typically treated through invasive surgical procedures. The company has stated that multiple clinical readouts are expected to begin in 2026, positioning it to move several programs deeper into late-stage development within the next two years.
A key component of Kardigan’s strategy is its integration of advanced cardiovascular datasets. Earlier in 2025, the company acquired Prolaio, a clinical intelligence firm known for its extensive cardiovascular data assets and regulatory-cleared algorithms. The acquisition provided Kardigan with one of the largest integrated cardiovascular clinical datasets available, which the company plans to use to optimize trial design, enhance patient-selection strategies, and support its precision-medicine approach. Executives have described this combination of therapeutics and data as central to their mission of creating more effective and personalized treatments.
Kardigan’s leadership has emphasized that the company aims to address longstanding gaps in cardiovascular drug development. Despite cardiovascular disease remaining the world’s leading cause of death, investment in cardiovascular therapeutics has historically lagged behind other medical fields. By focusing on targeted mechanisms and leveraging large-scale clinical data, the company seeks to accelerate the timeline from discovery to patient impact. The strong support from major institutional investors, they say, demonstrates confidence in both the therapeutic potential of the pipeline and the broader vision for transforming cardiovascular medicine.
With the close of the Series B round, Kardigan has raised approximately US $554 million to date, giving it significant resources to pursue late-stage clinical development, expand operational capacity, and prepare for regulatory interactions tied to its upcoming data milestones. As its pipeline advances and more clinical results emerge beginning in 2026, the company is positioned to become a significant player in the next generation of cardiovascular treatment innovation.
